Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
89 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H2 2014', provides an overview of the Complicated Skin And Skin Structure Infections (cSSSI)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Complicated Skin And Skin Structure Infections (cSSSI) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Complicated Skin And Skin Structure Infections (cSSSI) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Complicated Skin And Skin Structure Infections (cSSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Complicated Skin And Skin Structure Infections (cSSSI) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Complicated Skin And Skin Structure Infections (cSSSI) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Complicated Skin And Skin Structure Infections (cSSSI) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Complicated Skin And Skin Structure Infections (cSSSI) Overview 8 Therapeutics Development 9 Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Overview 9 Pipeline Products for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis 10 Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics under Development by Companies 11 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Complicated Skin And Skin Structure Infections (cSSSI) - Products under Development by Companies 16 Complicated Skin And Skin Structure Infections (cSSSI) - Companies Involved in Therapeutics Development 17 Cempra, Inc. 17 CrystalGenomics, Inc. 18 Debiopharm International S.A. 19 Dong-A Socio Group 20 Furiex Pharmaceuticals, Inc. 21 GlaxoSmithKline plc 22 Melinta Therapeutics, Inc 23 Microbion Corporation 24 Paratek Pharmaceuticals, Inc. 25 The Medicines Company 26 Complicated Skin And Skin Structure Infections (cSSSI) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 35 acorafloxacin - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Bismuth ethanedithiol - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 CG-400549 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Debio-1450 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Debio-1452 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 delafloxacin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 fusidic acid - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 GSK-2140944 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 lanopepden - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 omadacycline - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 oritavancin diphosphate - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 tedizolid phosphate - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Complicated Skin And Skin Structure Infections (cSSSI) - Recent Pipeline Updates 63 Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects 82 Complicated Skin And Skin Structure Infections (cSSSI) - Discontinued Products 83 Complicated Skin And Skin Structure Infections (cSSSI) - Product Development Milestones 84 Featured News & Press Releases 84 Apr 30, 2014: Cubist to Present New Pipeline Data Of Tedizolid Phosphate At 2014 European Congress of Clinical Microbiology and Infectious Diseases 84 Feb 27, 2014: European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Oritavancin 84 Oct 22, 2013: Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections 85 Sep 04, 2013: Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug 86 Appendix 88 Methodology 88 Coverage 88 Secondary Research 88 Primary Research 88 Expert Panel Validation 88 Contact Us 89 Disclaimer 89
List of Tables Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI), H2 2014 9 Number of Products under Development for Complicated Skin And Skin Structure Infections (cSSSI) - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Cempra, Inc., H2 2014 17 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by CrystalGenomics, Inc., H2 2014 18 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Debiopharm International S.A., H2 2014 19 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Dong-A Socio Group, H2 2014 20 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014 21 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by GlaxoSmithKline plc, H2 2014 22 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Melinta Therapeutics, Inc, H2 2014 23 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Microbion Corporation, H2 2014 24 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 25 Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline by The Medicines Company, H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 29 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 34 Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics - Recent Pipeline Updates, H2 2014 63 Complicated Skin And Skin Structure Infections (cSSSI) - Dormant Projects, H2 2014 82 Complicated Skin And Skin Structure Infections (cSSSI) - Discontinued Products, H2 2014 83
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.